Vaccitech (VACC) Peer Comparison

$3.52

$0.21 (6.34%)

As on 26-Dec-2023 09:30EDT

Market cap

$193 Mln

Revenue (TTM)

$7 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Edit

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	193	16,765	13,492	11,994	11,957
Revenue ($ Mln)	7	2,782	2,436	670	1,664
Net Profit ($ Mln)	-77.26	491.50	860.62	-319.95	413.60
Net Margin (%)	-1,064.33	17.67	35.33	-47.79	24.86
RoE (%)	-36.01	110.09	42.98	-71.14	430.03
Price to Earnings	--	35.25	17.40	--	30.89
Price-To-Book	0.36	39.29	7.42	26.87	84.52

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	7.26	1,460.00	1,611.06	243.23	660.12
Cost of Revenue	0.00	1,027.56	57.91	10.42	139.30
Gross Profit	44.70	432.44	1,553.15	243.23	520.81
Operating Expenses	94.21	153.74	1,351.67	421.74	253.28
Operating Profit (EBIT)	-89.96	278.70	201.48	-178.51	267.53
Other Income	0.00	7.07	-0.20	0.77	-1.67
Profit before Tax	-81.59	282.86	234.35	-172.71	248.92
Provision for Tax	-4.27	37.49	52.07	3.79	46.79
Profit after Tax (Net Income)	-77.26	245.37	182.28	-176.49	202.13
Minority Interest	0.08	--	--	19.82	--
Consolidated Profit	0.00	245.37	182.28	-176.06	202.13

Liabilities ($ Mln)

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	195.40	386.39	2,488.43	398.52	169.80
Minority Interest	0.08	--	--	19.82	--
Non-Current Liabilities	15.80	162.64	258.70	134.75	1,540.92
Current Liabilities	18.57	803.47	324.36	138.85	130.79
Total Liabilities	270.21	1,352.50	3,071.49	691.94	1,841.51

Assets ($ Mln)

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	58.91	1,018.53	1,452.73	286.64	1,102.50
Current Assets	171.07	333.96	1,618.76	405.30	739.01
Total Assets	270.21	1,352.50	3,071.49	691.94	1,841.51
Total Debt*	12.70	188.87	190.17	81.58	1,506.10
Net Current Assets	152.50	-469.51	1,294.40	302.30	608.22

Cashflow ($ Mln)

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-14.43	388.05	362.61	-136.13	240.11
Cash Flow from Investing Activities	--	-38.74	-524.41	-5.42	-487.01
Cash from Financing Activities	0.33	-775.78	0.59	65.19	362.37
Net Cash Inflow / Outflow	--	-426.47	-161.21	-76.36	115.48

Ratios

Profitability Ratios

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	2.09	29.58	7.38	-38.60	14.70
ROE (%)	-36.01	36.64	7.76	-43.72	110.23
ROA (%)	-28.72	16.29	6.41	-25.18	13.72
EBIT Margin (%)	-1,200.88	--	--	--	--
Net Margin (%)	-1,064.33	16.73	11.32	-72.33	30.70
Cash Profit Margin (%)	0.00	--	--	--	--

Growth Ratios

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-81.02	0.28	0.12	0.76	0.49
EBIT Growth (%)	-1,181.14	--	--	--	--
Net Profit Growth (%)	-780.11	34.93	-21.11	-25.31	-49.81
EPS Growth (%)	-859.90	0.57	-0.21	-0.24	-0.48
Book Value Growth (%)	-20.65	--	--	--	--

Valuation Ratios

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	16.43	28.07	28.45	-19.80	39.02
Price / Book Value	0.36	17.82	2.08	8.77	46.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-112.59	22.87	18.29	-19.04	28.62
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.49	0.08	0.20	8.87
Short term debt to equity ratio	0.01	0.13	0.01	0.01	0.08
Current Ratio	9.21	0.42	4.99	2.92	5.65
Quick Ratio	9.21	--	4.89	3.07	4.88
Interest Coverage	-28.38	98.37	3.75	-35.47	15.69

Operating Efficiency Ratios

	Vaccitech (VACC)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	143.28	17.36	13.33	0.58	35.00
Asset Turnover	0.03	0.97	0.57	0.35	0.45
Receivable days	67.97	55.02	56.39	8.76	89.10
Inventory Days	--	--	191.72	-302.34	201.93
Payable days	--	10.44	179.52	215.99	25.22
Cash Conversion Cycle	--	--	68.58	-509.57	265.81

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly